These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8730550)

  • 1. Immunophenotyping of AML and MDS and detection of residual disease.
    Sanz MA; Sempere A
    Baillieres Clin Haematol; 1996 Mar; 9(1):35-55. PubMed ID: 8730550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
    San-Miguel JF; Vidriales MB; Orfão A
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
    Zelezníková T; Babusíková O
    Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
    Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
    Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
    Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
    Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of morphological FAB classification and immunophenotyping: value in recognition of morphological, cytochemical and immunological characteristics of mixed leukaemias.
    Boban D; Sucić M; Marković-Glamocak M; Uzarević B; Batinić D; Marusić M; Nemet D; Labar B; Hitrec V
    Eur J Cancer; 1993; 29A(8):1167-72. PubMed ID: 8518029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia.
    Nakamura K; Ogata K; An E; Dan K
    Br J Haematol; 2000 Mar; 108(4):710-6. PubMed ID: 10792273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
    Rosenthal NS; Farhi DC
    Am J Clin Pathol; 1991 Apr; 95(4):556-60. PubMed ID: 2014782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.
    Macedo A; San Miguel JF; Vidriales MB; López-Berges MC; García-Marcos MA; Gonzalez M; Landolfi C; Orfão A
    J Clin Pathol; 1996 Jan; 49(1):15-8. PubMed ID: 8666678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
    Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
    Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes.
    Castoldi G; Cuneo A
    Baillieres Clin Haematol; 1996 Mar; 9(1):19-33. PubMed ID: 8730549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoid-associated antigen expression by acute myeloid leukemia.
    Launder TM; Bray RA; Stempora L; Chenggis ML; Farhi DC
    Am J Clin Pathol; 1996 Aug; 106(2):185-91. PubMed ID: 8712171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype.
    Vidriales MB; Orfao A; López-Berges MC; González M; López-Macedo A; García MA; Galende J; San Miguel JF
    J Clin Pathol; 1995 May; 48(5):456-62. PubMed ID: 7629293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
    Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
    Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.